Clozapine is the drug of choice for treatment-resistant schizophrenia. Prompted by a patient who developed reversible clozapine-induced myocarditis after long-term treatment with clozapine for several years for chronic-resistant schizophrenia, we undertook a review of the relevant literature. Concerning the myocarditis, the patient recovered rapidly by withdrawal of clozapine and with supportive management. Psychiatric stabilisation of the patient was at least possible with a combination of quetiapine (600 mg) and amisulpride (800 mg).
Well-designed studies with the aim to specifically investigate treatment options after clozapine are limited and clinical possibilities are discussed in this paper. Olanzapine and combinations using non-clozapine atypical neuroleptics have partly shown improvement, whereas evidence for successful augmentation with mood stabilisers, anticonvulsants or electroconvulsive therapy in treatment-resistant schizophrenia is limited.
Bandelow B., Degner D., Kreusch U., Ruther E. (1995) Myocarditis under therapy with clozapine. Schizophr Res17: 293-294
2.
Beelen A.P., Yeo K.T., Lewis L.D. (2001) Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol20: 215-219
3.
Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. (1994) Clozapine in schizophrenic outpatients: effects on positive and negative symptoms. Arch Gen Psychiatry151: 20-26
4.
Buckley N.A., Sanders P. (2000) Cardiovascular adverse effects of antipsychotic drugs. Drug Saf23: 215-228
5.
Buckley P.F., Goldstein J.M., Emsley R.A. (2004) Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res66: 143-150
6.
Casey D.E., Daniel D.G., Wassef A.A., Tracy K.A., Wozniak P., Sommerville K.W. (2003) Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology28: 182-192
7.
Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry158: 518-526
8.
Chan J., Sweeting M. (2006) Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol Epub
9.
Coulter D.M., Bate A., Meyboom R.H., Lindquist M., Edwards I.R. (2001) Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ322: 1207-1209
10.
de Knijff D.W., Schepers P.H., Blanken-Meijs J.T. (2001) Cardiomyopathy during clozapine therapy. Ned Tijdschr Geneeskd145: 1697-1699
11.
Dossenbach M R K, Beuzen J.N., Avnon M., Belmaker R.H., Elizur A., Mark M., Munitz H., Schneidman M., Shoshani D., Kratky P., Grundy S.L., Tollefson G.D. (2000) The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine . Clin Ther22: 1021-1034
Dursun S.M., Deakin J.F. (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol15: 297-301
14.
Emsley R.A., Raniwalla J., Bailey P.J., Jones A.M. (2000) A comparison of the effects of quetiapine (`seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group . Int Clin Psychopharmacol15: 121-131
15.
Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Moller H.J., WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: long-term treatment of schizophrenia (2006). World J Biol Psychiatry7: 5-40
16.
Green A.I., Burgess E.S., Dawson R., Zimmet S.V., Strous R.D. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res60: 81-85
17.
Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. (2007) Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf30: 47-57
18.
Hedges D.W., Jeppson K.G. (2002) New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother36: 437-439
19.
Henderson D.C., Nasrallah R.A., Goff D.C. (1998) Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry59: 585-588
20.
Heresco-Levy U., Javitt D C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry57: 577-585
21.
Jensen V.E., Gotzsche O. (1994) Allergic myocarditis in clozapine treatment. Ugeskr Laeger156: 4151-4152
22.
Kakar P., Millar-Craig M., Kamaruddin H., Burn S., Loganathan S. (2006) Clozapine induced myocarditis: a rare but fatal complication. Int J Cardiol112: 5-6
23.
Kane J M., Honigfeld G., Singer J., Meltzer H.Y., the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry45: 789-779
24.
Kane J.M., Khanna S., Rajadhyaksha S., Giller E. (2006) Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol21: 21-28
25.
Karunakaran K., Tungaraza T.E., Harborne G. (2007) Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?J Psychopharmacol21(4): 453-456
Lee S.Y., Kim Y.J., Kim K.T., Choe H., Jo S.H. (2006) Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol148: 499-509
31.
Lerner V., Chudakova B., Kravets S., Polyakova I. (2000) Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol23: 284-286
32.
Lerner V., Libov I., Kotler M., Strous R.D. (2004) Combination of `atypical' antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry28: 89-98
33.
Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med353: 1209-1223
34.
Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T. Jr, Friedman A., Kleinberg D., Yevich S.J., Davis B., Shon S. ( 2004) Physical health monitoring of patients with schizophrenia . Am J Psychiatry161: 1334-1349
35.
McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., CATIE Investigators (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry163: 600-610
36.
Meeker J.E., Herrmann P.W., Som C.W., Reynolds P.C. (1992) Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol16: 54-56
37.
Meltzer H.Y. (2005) Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry66: 530-533
38.
Meyer-Linden Serg A., Gruppe H., Bauer U., Lis S., Krieger S., Gallhofer B. (1997) Improvement of cognitive function in schizophrenic patients recolving clozapine or zotepine: results from a double-blind study . Pharmacopsychiatry30: 35-42.
39.
National Institute for Clinical Excellence ( 2002) Clinical Guideline 1. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. NICE, London
40.
Raskin S., Durst R., Katz G., Zislin J. (2000) Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia . J Clin Psychopharmacol20: 500-503
41.
Reinders J., Parsonage W., Lange D., Potter J.M., Plever S. (2004) Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry38: 915-922
42.
Rey J.M., Walter G. (1997) Half a century of ECT use in young people. Am J Psychiatry154: 595-602
43.
Shaw P., Sporn A., Gogtay N., Overman G.P., Greenstein D., Gochman P., Tossell J.W., Lenane M., Rapoport J.L. (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry63: 721-730
44.
Tiihonen J., Hallikainen T., Ryynanen O.P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., Putkonen A. (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry54: 1241-1248
45.
Tollefson G D, Birkett M A, Kiesler G M, Wood A J, Lilly Resistant Schizophrenia Study Group (2001) Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry49: 52-63
46.
Vaddadi K.S., Soosai E., Vaddadi G. (2003) Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol55: 307-309
47.
Volavka J., Czobor P., Sheitman B., Lindenmeyer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. (2002) Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry159: 255-262
48.
Walker A.M., Lanza L.L., Arellano F., Rothman K.J. (1997) Mortality in current and former users of clozapine . Epidemiology8: 671-677
49.
Wooltorton E. (2002) Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ166: 1185-1186
50.
Ziegenbein M., Calliess I.T. (2006) Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci18: 246-247
51.
Ziegenbein M., Kropp S., Kuenzel H.E. (2005) Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol28: 220-224
52.
Zink M. ( 2006) Optimizing the antipsychotic potency of olanzapine by augmentation-a critical review. Psychiatr Prax33: 261-268
53.
Zink M., Mase E., Dressing H. (2004) Ziprasidone-augmentation of clozapine. Psychiatr Prax31: 259-261
